Epidemiology and prevention of respiratory syncytial virus infections in children in Italy
| Autor: | Elena Bozzola, Paolo Bonanni, Fabio Mosca, Alessandra Coscia, S Parisi, Paolo Manzoni, Giovanni Checcucci Lisi, Fabrizio Sandri, Teresa Mazzone, Marcello Lanari, Giorgio Piacentini, Chiara Azzari, Eugenio Baraldi |
|---|---|
| Přispěvatelé: | Azzari C., Baraldi E., Bonanni P., Bozzola E., Coscia A., Lanari M., Manzoni P., Mazzone T., Sandri F., Checcucci Lisi G., Parisi S., Piacentini G., Mosca F. |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pediatrics
medicine.medical_specialty RSV vaccines First year of life Respiratory Syncytial Virus Infections Review Respiratory syncytial virus Antiviral Agents Virus RJ1-570 RSV prevention RSV vaccine Epidemiology medicine Bronchiolitis Viral Humans Viral Respiratory system Asthma Cause of death Palivizumab Antiviral Agent RSV pediatric burden Monoclonal antibodie business.industry Infant Newborn LRTI Monoclonal antibodies RSV RSV epidemiology Gestational age Infant medicine.disease Newborn Italy Bronchiolitis Respiratory syncytial viru Population Surveillance business Human |
| Zdroj: | Italian Journal of Pediatrics Italian Journal of Pediatrics, Vol 47, Iss 1, Pp 1-12 (2021) |
| Popis: | Respiratory syncytial virus (RSV) is the leading global cause of respiratory infections in infants and the second most frequent cause of death during the first year of life. This highly contagious seasonal virus is responsible for approximately 3 million hospitalizations and 120,000 deaths annually among children under the age of 5 years. Bronchiolitis is the most common severe manifestation; however, RSV infections are associated with an increased long-term risk for recurring wheezing and the development of asthma. There is an unmet need for new agents and a universal strategy to prevent RSV infections starting at the time of birth. RSV is active between November and April in Italy, and prevention strategies must ensure that all neonates and infants under 1 year of age are protected during the endemic season, regardless of gestational age at birth and timing of birth relative to the epidemic season. Approaches under development include maternal vaccines to protect neonates during their first months, monoclonal antibodies to provide immediate protection lasting up to 5 months, and pediatric vaccines for longer-lasting protection. Meanwhile, improvements are needed in infection surveillance and reporting to improve case identification and better characterize seasonal trends in infections along the Italian peninsula. Rapid diagnostic tests and confirmatory laboratory testing should be used for the differential diagnosis of respiratory pathogens in children. Stakeholders and policymakers must develop access pathways once new agents are available to reduce the burden of infections and hospitalizations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|